Kythera Biophrarma (KYTH) Enters Hair Loss IP Agreement with Actelion Pharma, Univ. of Pennsylvania
- S&P 500 ends lower after another wild ride
- Apple (AAPL) Tops Q1 EPS by 21c; Revenues Beat
- Visa (V) Shares Up 3% on Strong Q1 Beat
- 'An EV Cash Machine': Tesla (TSLA) Beats on Revenue and Profit But Supply Chain Warning Sends Shares Lower, Analysts Positive and Raise Numbers
- Western Digital (WDC) Shares Dropped 10% Despite Q2 Beat
Kythera Biophrarma (NASDAQ: KYTH) has entered into separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania for a novel approach for the treatment of hair loss, which together could enable KYTHERA to bring a new treatment to the very large and still highly unsatisfied hair loss market.
"These two licenses build on KYTHERA's focus on developing and commercializing high-value, self-pay aesthetic products that have the promise to yield high patient satisfaction and enhanced self image," said Keith Leonard, KYTHERA's president and CEO. "Based on several years of research and clinical work already accomplished, we believe we have the possibility of reaching initial proof-of-concept data in a very capital efficient manner."
Under the terms of the agreement with Actelion, KYTHERA Holdings Ltd., a wholly-owned Bermuda subsidiary of KYTHERA Biopharmaceuticals, Inc., licensed the worldwide rights to setipiprant, a clinical-stage selective and potent oral antagonist to the prostaglandin D2 (PGD2) receptor. As part of the agreement, Actelion will be eligible to receive up to $27 million in potential development and regulatory milestones, as well as royalties on sales if setipiprant is successfully commercialized.
Under the terms of the agreement with the University of Pennsylvania, KYTHERA Holdings Ltd., acquired exclusive worldwide rights to certain patent rights owned by the University of Pennsylvania covering the use of PGD2 receptor antagonists for the treatment of hair loss (often presenting as male pattern baldness, or androgenic alopecia) under a license agreement facilitated by the Penn Center for Innovation. The discovery of the relationship between PGD2 and hair loss was made in the laboratory of Dr. George Cotsarelis and published in late 20111. KYTHERA has been supporting research in Dr. Cotsarelis' lab at the University of Pennsylvania over the last two years under sponsored research and option agreements to further develop and elucidate the initial reported observations.
"The University of Pennsylvania's discovery and associated intellectual property assets, combined with access to the PGD2 antagonist setipiprant, provide KYTHERA a strong foundation for this novel approach to hair loss," said Frederick Beddingfield, III, M.D., Ph.D., KYTHERA's Chief Medical Officer. "These observations are potentially the most innovative new thinking in hair loss over the last two decades. Setipiprant is believed to directly affect this hair loss pathway, and our own preclinical and in vitro human hair models confirmed this effect. It is a well-characterized molecule with a large safety database and we believe we can quickly initiate a development program to study it in hair loss. Putting these two pieces of the puzzle together is ideal and represents an example of our approach to scientifically sound and efficient drug development."
KYTHERA plans to conduct a human proof-of-concept study to establish the efficacy of setipiprant in male subjects with androgenic alopecia (AGA).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TG Therapeutics (TGTX) CEO shared data and regulatory update
- PyroGenesis Canada (PYR) Announces Factory Acceptance Test for Plasma Torches Scheduled with Client A
- Home Depot (HD) Names Ted Decker CEO
Create E-mail Alert Related CategoriesCorporate News, FDA, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!